Cancer feature: cnaPANCAN280

ABCB10 ACTA1 ACTN2 ADSS AGT AKT3 ARID4B ARV1 B3GALNT2 C1orf100 C1orf101 C1orf131 C1orf198 CAPN9 CCSAP CEP170 CHML CHRM3 COA6 COG2 COX20 DESI2 DISC1 EDARADD EGLN1 ERO1LB EXO1 EXOC8 FAM89A FH FMN2 GALNT2 GGPS1 GNG4 GNPAT GPR137B GREM2 HEATR1 HNRNPU IRF2BP2 KCNK1 KMO LGALS8 LYST MAP10 MAP1LC3C MLK4 MT1HL1 MTR MTRNR2L11 NID1 NTPCR NUP133 OPN3 PCNXL2 PGBD5 PLD5 RAB4A RBM34 RGS7 RYR2 SDCCAG8 SIPA1L2 SLC35F3 SPHAR SPRTN TAF5L TARBP1 TBCE TOMM20 TRIM67 TSNAX TSNAX-DISC1 TTC13 URB2 WDR64 ZBTB18 ZP4

Known Driver Genes: FH

Copy number alternation: gain

Pevonedistat

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer